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Abstract
Background: Transforming growth factor beta 1 (TGF-b1) is an inhibitor of muscle cell differentiation that is associated with
fibrosis, poor regeneration and poor function in some diseases of muscle. When neutralizing antibodies to TGF-b1 or the
angiotensin II inhibitor losartan were used to reduce TGF-b1 signaling, muscle morphology and function were restored in
mouse models of Marfan Syndrome and muscular dystrophy. The goal of our studies was to identify additional agents that
overcome the anti-myogenic effect of TGF-b1.
Methodology/Principal Findings: A high-content cell-based assay was developed in a 96-well plate format that detects the
expression of myosin heavy chain (MHC) in C2C12 cells. The assay was used to quantify the dose-dependent responses of
C2C12 cell differentiation to TGF-b1 and to the TGF-b1 Type 1 receptor kinase inhibitor, SB431542. Thirteen agents
previously described as promoting C2C12 differentiation in the absence of TGF-b1 were screened in the presence of TGF-b1.
Only all-trans retinoic acid and 9-cis retinoic acid allowed a maximal level of C2C12 cell differentiation in the presence of
TGF-b1; the angiotensin-converting enzyme inhibitor captopril and 10 nM estrogen provided partial rescue. Vitamin D was a
potent inhibitor of retinoic acid-induced myogenesis in the presence of TGF-b1. TGF-b1 inhibits myoblast differentiation
through activation of Smad3; however, retinoic acid did not inhibit TGF-b1-induced activation of a Smad3-dependent
reporter gene in C2C12 cells.
Conclusions/Significance: Retinoic acid alleviated the anti-myogenic effect of TGF-b1 by a Smad3-independent mechanism.
With regard to the goal of improving muscle regeneration and function in individuals with muscle disease, the identification
of retinoic acid is intriguing in that some retinoids are already approved for human therapy. However, retinoids also have
well-described adverse effects. The quantitative, high-content assay will be useful to screen for less-toxic retinoids or
combinations of agents that promote myoblast differentiation in the presence of TGF-b1.
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Introduction
Transforming growth factor beta 1 (TGF-b1) plays a prominent
role in regulating a variety of cellular functions including cell
migration, cell proliferation, apoptosis, differentiation, immuno-
suppression, inflammation, tumor-suppression, and angiogenesis
[1,2]. It has long been recognized that the specific cellular
response to TGF-b1 is context dependent and varies according to
the cell type, the cellular environment and the activity of other
signaling pathways [3]. Elevated TGF-b1 has been associated with
several disease states including metastasis and immune evasion by
cancer cells, and fibrosis in many tissues including skin, lung and
kidney [4,5].
One of the earliest cellular responses reported for TGF-b1 was
inhibition of myoblast differentiation in culture [6,7]. TGF-b1
inhibits expression of two key transcriptional mediators of muscle
cell differentiation, MyoD and myogenin [8]. The TGF-b1
activated protein Smad3 binds directly to the MyoD bHLH
domain to block MyoD/E protein dimerization and DNA binding
[9]. Smad3 also binds to and interferes with the myogenic
transcription factor MEF2 to prevent muscle-specific gene
expression [10]. In contrast, increased expression of the inhibitory
Smad, Smad7, promotes myogenesis [11]. Another TGF-b family
member, myostatin, is also a potent inhibitor of muscle
differentation and growth [12,13].
The anti-myogenic role of TGF-b1 has been associated with
muscle disease. For example, TGF-b1 levels are elevated in
dystrophic and injured muscle [14,15]. In injured muscle, TGF-
b1-induced myofibroblasts cause excessive fibrosis [16,17,18,19].
Recently, Cohn, Dietz, and colleagues reported that the elevated
TGF-b1 signaling in the muscles of mouse models of Marfan
syndrome (MFS) and muscular dystrophy contributed to the
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dominant disorder caused by mutations in the gene encoding
fibrillin-1. Fibrillin-1 negatively regulates TGF-b1 activation and
signaling. Fibrillin-1 mutant mice have decreased muscle fiber size
and number associated with increased levels of the active signaling
intermediates of TGF-b1 signaling, phospho-Smad2 and phospho-
Smad3 [20]. Elevated levels of nuclear-localized activated Smads
were also detected in skeletal muscle from X-linked muscular
dystrophic (mdx) mutant mice, even in the absence of myostatin
[20]. Fewer proliferating satellite cells, the cells responsible for
muscle regeneration [21,22], were detected in the muscle of
fibrillin-1 mutant mice, suggesting that TGF-b1 might exert its
effect by inhibiting satellite cell proliferation and differentiation.
Reduced satellite cell function is also associated with poor muscle
regeneration in muscular dystrophy [23]. Interestingly, spikes of
elevated TGF-b1 expression and phospho-Smads occur in wild-
type muscle after damage by injection of a snake venom
cardiotoxin, but these increases were not detected 18 days after
injury in wildtype mice. In contrast, the increases were maintained
in the skeletal muscle of the fibrillin-1 mutant mice, suggesting
that the prolonged increase in TGF-b1 expression impedes
regeneration.
Treatment of the fibrillin-1 mutant mice or the mdx mutant
mice with TGF-b1-neutralizing antibody or the angiotensin II
type 1 receptor inhibitor losartan improved muscle architecture,
repair and function [20]. Both TGF-b1-neutralizing antibody and
losartan treatment of 9-month-old mdx mice improved muscle
regeneration assayed four and eighteen days after snake toxin-
induced injury of muscle from mdx mice, e.g., increased neonatal
myosin-positive fibers were detected. Importantly, long term (6–9
months) administration of losartan to mdx mice beginning at 6
weeks, provided detectable improvement in the diaphragm and
gastrocnemius muscles with decreased evidence of fibrosis. In
behavioral tests, treated mdx mice had increased grip strength and
reduced muscle fatigue compared to the placebo-treated mdx
mice. Losartan treatment led to increased muscle mass and force
generation in the extensor digitorum longus muscles correlating
with an increase in the number of muscle fibers [20]. ln addition to
MFS and muscular dystrophy, losartan is also known to inhibit
TGF-b1 signaling in other disease states such as renal disease and
cardiomyopathy [24,25]. Studies in animal models of kidney
fibrosis have reported enhanced efficacy by combining losartan
with TGF-b inhibitors [26,27,28].
Inhibition of TGF-b signaling has focused on disruption of the
ligand-receptor interaction with neutralizing antibodies or by
inhibition of the receptors using small molecule inhibitors of the
receptor kinase activity [29]. TGF-b1 signaling is effectively
inhibited by small molecule compounds targeted to the TGF-b
Type 1 receptor kinase, Alk5 [30]. One such compound,
SB431542, blocks the increased phosphorylation of Smad2 caused
by myostatin activation of the TGF-b Type 1 receptor kinases in
C2C12 myoblasts [31]. Treatment with 10 mM SB431542 led to
the formation of myotubes with an enlarged diameter upon
differentiation of C2C12 cells in vitro. However, prolonged
treatment (96 hours) with 10 mM SB431542 led to decreased
expression of myosin heavy chain in the C2C12-derived myotubes;
the inhibitor also caused an increase in the cross-sectional area of
isolated iliofibularis skeletal muscle fibers from Xenopus laevis, but
without a concomitant increase in tetanic force, leading to the
conclusion that SB431542 causes a nonfunctional hypertrophy in
muscle fibers that may not be of therapeutic benefit [31].
Targeting the TGF-b receptor may be undesirable because
TGF-b plays important roles in normal physiology including
tumor suppression, wound healing, or inflammation. Consistent
with this concern, recent clinical trial results indicate that agents
directly targeting the TGF-b receptor may have adverse effects
[32,33].
Given the clear evidence for elevated TGF-b1 signaling in
myopathy and the reported concerns associated with blocking
TGF-b1 signaling at the level of the receptor kinase, we sought to
develop a quantitative cell-based screen for agents that overcome
the anti-myogenic effect of TGF-b1 on the muscle satellite cell line
C2C12. We evaluated several agents in the assay for their ability to
overcome the TGF-b1 inhibition of muscle differentiation.
Inhibition of the TGF-b1 Type 1 receptor kinase with
SB431542 allowed C2C12 differentiation in the presence of
TGF-b1 as expected. Of the other 13 agents tested, only all-trans
retinoic acid and 9-cis retinoic acid overcame the TGF-b1 effect
completely. Neither of the retinoic acid compounds prevented
TGF-b1 activation of the Smad3-dependent reporter gene SBE12-
lux in C2C12 cells, indicating that their ability to overcome the
anti-myogenic effect of TGF-b1 is likely through a Smad3-
independent mechanism.
Materials and Methods
Cell culture
Mouse myoblast C2C12 cells were obtained from the American
Type Culture Collection (CRL-1772) and cultured in growth
media consisting of 10% fetal bovine serum in Dulbecco’s
Modified Eagle’s Medium (DMEM). To induce differentiation,
cells were washed one time in 2% horse serum (HS)/DMEM
(Invitrogen, Carlsbad, CA) in DMEM and cultured in 2% HS/
DMEM for 96 hours [34].
Differentiation Assay
Cells were plated at 7,500 cells per well in black 96-well optical
plates (BD Biosciences, San Jose, CA) and allowed to adhere for
one day. The next day, cells were washed one time in 2% horse
serum/DMEM, and cultured +/2 TGF-b1 (R & D Systems,
Minneapolis, MN) and +/2 candidate differentiation agent. After
4 more days in culture, cells were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) for 15 minutes, permeabilized in
0.5% Triton X-100 in PBS for 5 minutes, and blocked in 3%
bovine serum albumin (BSA) in PBS for 30 minutes. The antibody
MF-20 (Developmental Studies Hybridoma Bank, Iowa City, IA),
diluted to 5 mg/mL in 3% BSA/PBS, was used to detect myosin
heavy chain (MHC). To remove unbound primary or secondary
antibody, 3 five-minute washes were performed in 0.05% Triton
X-100/PBS with a final wash in PBS. Incubation with the
secondary antibody, Alexa Fluor 594 goat anti-mouse IgG (Cat.
No. A-11032, Invitrogen) diluted to 7 mg/mL in 3% BSA/PBS,
was used to detect MF-20. Co-incubation of Hoechst 33342
(Invitrogen) (diluted to 7 mg/mL in 3% BSA/PBS) with the
secondary antibody was used to stain the nuclei. All antibody and
nuclear stain incubations were performed at room temperature for
1 hour.
Image acquisition and analysis
Three non-contiguous images from each well were obtained
using a high-content imager, the BD Pathway 855 (BD
Biosciences, San Jose, CA). Images were obtained of both nuclei
and cytoplasmic regions using a 106objective. Image analysis was
performed using BD AttoVision software v.1.6. A segmentation
strategy, Ring 2 Outputs Band, was used to identify and count
each nucleus in the Hoechst channel and the respective Alexa 594-
stained cytoplasmic band was quantified by dialing out from each
nucleus by a fixed distance. Image Data Explorer was used to
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each cytoplasmic band, as well as a percent muscle differentiation
value. To determine how many cells were positive for myosin
heavy chain, an intensity threshold of 350–450 pixels was set to
count the nuclei whose cytoplasmic bands were positive for Alexa
Fluor 594 over background. The data were transformed into the
percent of nuclei surrounded by MHC expression. Percent muscle
differentiation was obtained by dividing the number of nuclei
positive for MHC by the total number of nuclei and multiplying by
100. This approach avoided artifacts due to well-to-well variation
in overall staining intensity. Data were plotted using XLfit 5.2
(IDBS, Alameda, CA) or Microsoft Excel. The effective dose
producing a 50% response (ED50) or the half maximal inhibitory
concentration (IC50) was calculated using XLfit 5.2. Agents
screened: All-trans retinoic acid (atRA), 9-cis retinoic acid (9-
cisRA), epigallocatechin-3-gallate (EGCG), ascorbic acid, tranilast,
losartan potassium, captopril, resveratrol, 1a,25-dihydroxyvitamin
D3 (vitamin D) and PD123,319 were purchased from Sigma-
Aldrich (St. Louis, MO). TGF-b1 and Relaxin-2 were obtained
from R & D Systems. SB431542 was obtained from Tocris
Bioscience (Ellisville, MO). Estrogen was a gift from Dr. Wei Xu
(UW-Madison). R1881 was a gift from Dr. George Wilding (UW-
Madison). 17-Dimethylamino-ethylamino-17-demethoxygeldana-
mycin (17-DMAG) was a gift from Dr. Shannon Kenney (UW-
Madison). Specific inhibitor of Smad3 (SIS3) was purchased from
EMD Chemicals (Gibbstown, NJ). All experiments were conduct-
ed with 0.1% or less of DMSO (Sigma-Aldrich). L-ascorbic acid
(Sigma-Aldrich) at a concentration 1 mM was added to experi-
mental samples containing EGCG in order to increase its stability
and minimize oxidation.
Reporter Gene Assays
C2C12 cells were plated at a density of 20,000 cells per well in
24-well plates. 24 hours later, cells were transfected with a Smad
binding element 12 (SBE 12)-luciferase reporter gene and a b-
galactosidase construct with transfection reagent TransIT-LT1
(Mirus Bio, Madison, WI). After 24 hours, cells were treated with a
DMSO control, 1 mM SB431542, and 50 pM TGF-b1 with or
without different concentrations of 9-cis retinoic acid and all-trans
retinoic acid, in triplicate. After 24 hours, cells were lysed with the
Galacto-Star b-Galactosidase Reporter Gene Assay System for
Mammalian Cells (Applied Biosystems, Calsbad, CA). Luciferase
levels were determined using Bright-Glo luciferase reagent
(Promega, Madison, WI) and b-galactosidase levels were measured
with the Galacto-Star Kit. Luminescence was measured using a
Wallac 1420 Victor Plate Reader. Luciferase values were
normalized to b-galactosidase levels to account for well-to-well
differences in transfection efficiency.
Statistical analysis methods: Data were obtained from a
minimum of 3 independent experiments. The average and
standard deviations were calculated and are presented on each
figure. For Table 1, the statistical significance was assessed using
the two-sided Wilcoxon Rank Sum Test provided in the mStat
package (http://www.mcardle.wisc.edu/mstat/).
Results and Discussion
Detection of C2C12 differentiation by imaging in a 96-
well plate format
In order to screen for agents that overcome the anti-myogenic
effect of TGF-b1 on C2C12 differentiation, an assay was
established that quantified C2C12 cell differentiation as indicated
by expression of myosin heavy chain (MHC). To permit the
eventual screening of large numbers of compounds, the assay was
Table 1. Compounds tested for their ability to overcome the
anti-myogenic effect of TGF-b1 in C2C12 cells.
Treatment Dose % Rescue p-value
AT G F - b1, alone 50 pM 0
B SB431542 1 mM1 0 0
C Losartan 1 mM 215
10 mM 217
25 mM 21
100 mM 22
Captopril 10 mM1
100 mM8 p ,0.01
500 mM2 4 p ,0.001
750 mM2 0 p ,0.001
1m M 1 4 p ,0.001
PD123,319 10 mM 24
100 mM 216 p,0.001
D Tranilast 5 mM 210 p,0.001
50 mM 210 p,0.001
200 mM 227 p,0.001
SIS3 0.3 mM3
1 mM 24p ,0.05
3 mM 26p ,0.001
17-DMAG 1 nM 22
5n M 21
10 nM 27p ,0.05
Relaxin 1.7 nM 0
17 nM 0
167 nM 22
E EGCG 50 nM 5
500 nM 4
Resveratrol 10 nM 3
100 nM 5
1u M 24
F R1881 5 nM 21
25 nM 26p ,0.05
100 nM 2
Estrogen 1 nM 0
5n M 3
10 nM 9 p,0.05
G 9-Cis Retinoic Acid 1 nM 10 p,0.001
25 nM 79 p,0.001
50 nM 105 p,0.001
100 nM 129 p,0.001
250 nM 185 p,0.001
All-Trans Retinoic Acid 1 nM 10 p,0.01
25 nM 22 p,0.001
50 nM 48 p,0.001
100 nM 71 p,0.001
250 nM 119 p,0.001
doi:10.1371/journal.pone.0015511.t001
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was used to minimize the number of manipulations and cost of
reagents per well and to maximize the efficiency and throughput of
screening compounds. Quantification of the percent of nuclei
surrounded by MHC-staining was achieved using the high content
imaging capabilities and analysis software of the BD Pathway.
C2C12 cells were stimulated to differentiate into multi-nucleated,
MHC-expressing myotubes in the 96-well plate format by the
addition of 2% horse serum in DMEM. After 96 hours, C2C12
cells were stained to detect MHC-expressing myotubes (Figure 1A–
1D, 1I–1L) and nuclei (Figure 1E–1H, 1M–1P). Panels 1I–1P
show a 36 enlargement of a region from each of the 8 images
shown in panels 1A–1H. Vehicle control (DMSO) or SB431542
did not alter differentiation (Figure 1A–1B, 1I–1J) or proliferation
(Figure 1E–1F, 1M–1N). TGF-b1 inhibited myoblast differentia-
tion into myotubes (Figure 1C, 1K). Addition of SB431542, a
TGF-b Type 1 receptor inhibitor, to the TGF-b1-containing
media permitted differentiation (Figure 1D, 1L). The number of
nuclei was increased in TGF-b1 treated wells (Figure 1G, 1O) but
remained at control levels with TGF-b1 plus SB431542
(Figure 1H, 1P). We noted that differentiation of C2C12 cells in
the 96-well plate was sensitive to many variables in the assay
including cell passage number, cell density, media conditions and
time. For example, at higher cell densities and longer times, MHC
expression and myotube formation were readily observed in 10%
FBS/DMEM as well as the standard ‘‘differentiation media’’
which contains 2% horse serum in DMEM.
C2C12 imaging assay allows evaluation of dose-response
properties
A dose-response curve of TGF-b1 was performed to determine
the potency of TGF-b1 inhibition of C2C12 differentiation
(Figure 2). Increasing concentrations of TGF-b1 induced cell
proliferation with an ED50 (50% of the maximal increase in the
number of nuclei) of 17 pM (Figure 2A). TGF-b1 caused a dose-
dependent repression of myoblast differentiation with an IC50
(50% inhibition of MHC positive nuclei) of 23 pM (Figure 2B). For
subsequent assays to detect agents that overcome the TGF-b1
effect we used 50 pM TGF-b1; this concentration provided close
to maximal repression but might be more sensitive to interference
than much higher concentrations of TGF-b1.
The C2C12 cell-based assay also was used to determine the
potency of SB431542 on preventing the TGF-b1 anti-myogenic
effect. The number of nuclei was reduced approximately two fold by
Figure 1. C2C12 muscle differentiation is inhibited by TGF-b1 and restored by SB431542. Cells were treated with vehicle control (DMSO)
(A and E), 1 mM SB431542 (B and F), 50 pM TGF-b1 (C and G), or SB431542 and TGF-b1 (D and H). After 96 hours, cells were stained with antibodies
against MHC (A–D) or with Hoechst 33342 (E–H). DMSO (0.1%) and SB431542-treated cells were indistinguishable from untreated C2C12 cells (not
shown) for differentiation (A, B) or number of nuclei (proliferation) (E, F). TGF-b1 inhibited differentiation as evidenced by reduced staining for MHC
(C). Addition of SB431542 with TGF-b1 prevented the TGF-b1-mediated reduction in MHC staining (D). The number of nuclei was increased in TGF-b1-
treated cells (G) but was comparable to control levels when SB431542 was also present (H). Images (A–H) show an entire field obtained during BD
Pathway image acquisition (scale bar=100 mm). The bottom 8 panels (I–P) show a 36enlargement (scale bar=33 mm) of a region from each of the 8
full field images in A–H.
doi:10.1371/journal.pone.0015511.g001
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tion of SB431542 needed to achieve 50% of this two-fold reduction
(IC50) was 323 nM. The two-fold reduction in number of nuclei was
on the same order as the increase in the number of nuclei observed in
t h ep r e s e n c eo fT G F - b1 (Figure 2A), suggesting that SB431542 was
preventing the effect of TGF-b1.ThepercentofMHCpositivenuclei
was determined in myoblasts treated with 50 pM TGF-b1a n dw i t h
increasing concentrations of SB431542 (Figure 3B). The concentra-
tion of SB431542 needed to restore 50% of the maximal number of
MHC positive nuclei (EC50) was 166 nM.
Although several compounds are reported to stimulate C2C12
cell differentiation in vitro, there has been no systematic analysis of
compounds promoting C2C12 differentiation in the presence of
TGF-b1. To identify compounds that prevent the TGF-b1-
mediated suppression of myogenesis in the C2C12 imaging assay,
compounds were added at several different concentrations to the
wells of C2C12 cells at the same time as differentiation media and
50 pM TGF-b1 (Table 1). The number of nuclei and percent
MHC positive nuclei were quantified after 96 hours. The percent
rescue of differentiation was calculated by subtracting the
background, which was assumed to be the percent MHC positive
nuclei in the presence of TGF-b1, dividing by the background-
subtracted percent MHC positive nuclei in the presence of
SB431542+ TGF-b1 and multiplying by 100. This resulted in 0%
rescue with TGF-b1 (Table 1A) and 100% rescue for the
SB431542+ TGF-b1 (Table 1B). The percent rescue provided
by each treatment was evaluated for statistical significance by a
two-sided Wilcoxon Rank Sum test. Only significant p-values are
shown. Some treatments caused significant but negative rescue
percentages, indicating reduced, rather than improved differenti-
ation in the presence of TGF-b1 (Table 1). Our focus was on
treatments that significantly improved rescue of differentiation.
Partial recovery of C2C12 differentiation by the
Angiotensin-converting enzyme (ACE) inhibitor captopril
The first compounds to be evaluated in the assay were inhibitors
of the angiotensin pathway because the TGF-b1 effect was
alleviated in mouse models of MFS and muscular dystrophy by
losartan, an angiotensin II type 1 receptor antagonist [20]. We did
not observe increased C2C12 differentiation by losartan in vitro in
the presence of TGF-b1 (Table 1C), which was consistent with a
previous report indicating that losartan does not increase MHC
Figure 2. Dose-Response of TGF-b1 on C2C12 Proliferation and Differentiation. C2C12 cells were treated with different concentrations of
TGF-b1 for 96 hours and stained for nuclei and MHC. (A) Cell proliferation, as denoted by number of nuclei, increased in a dose-dependent manner
with an EC50 for TGF-b1 of 17 pM. (B) Myoblast differentiation, as measured by percentage of nuclei positive for MHC, decreased with increasing
concentrations of TGF-b1 with an IC50 of 23 pM.
doi:10.1371/journal.pone.0015511.g002
Figure 3. Dose-Response of SB431542 on C2C12 proliferation and differentiation in the presence of TGF-b1. TGF-b1 (50 pM) was used
to inhibit C2C12 differentiation. (A) Increasing concentrations of SB431542 caused a decrease in the number of nuclei with an IC50 of 323 nM. (B)
SB431542 overcame the TGF-b1 inhibition of C2C12 differentiation with an EC50 of 166 nM. At 10 mM SB431542, we observed a slight but
reproducible reduction in the percent of MHC positive nuclei.
doi:10.1371/journal.pone.0015511.g003
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to the angiotensin II pathway, captopril and PD123,319 were also
examined. Captopril is an angiotensin converting enzyme (ACE)
inhibitor that inhibits the conversion of angiotensin I to
angiotensin II. ACE inhibitors are used to treat high blood
pressure and help to alleviate the effects of a heart attack and
diabetic nephropathy. Captopril has been shown to reduce TGF-
b1-induced kidney and colon fibrosis in vivo [36,37]. ACE activity
negatively affects C2C12 muscle differentiation in vitro, and ACE
inhibitors increase MHC expression in differentiating myoblasts
and promote myotube formation [35,38]. We observed a
statistically significant (p,0.01) but modest 8% increase in
differentiation in the presence of TGF-b1 when 100 mM Captopril
was present and an average of 19% rescue with concentrations up
to 1 mM (p,0.001) (Table 1C). This is similar to the effective in
vitro concentration range of Captopril reported previously [35,38].
PD123,319 is an angiotensin II type 2 receptor antagonist that has
been shown to enhance myoblast formation when added at 10 mM
and 100 mM to differentiation media [35]. Angiotensin II type 2
receptor antagonists are used to treat diabetes-induced kidney
damage, hypertension, and damage from congestive heart failure.
However, under the conditions of our assay, PD123,319 was
unable to restore C2C12 cell differentiation (Table 1C).
Four TGF-b signaling inhibitors fail to restore C2C12
differentiation
The TGF-b1 Type 1 receptor kinase inhibitor SB431542 was
used as a positive control to establish the assay, so we examined
four other reported inhibitors of TGF-b1 signaling: tranilast,
specific inhibitor of Smad3 (SIS3), 17-Dimethylamino-ethylamino-
17-demethoxygeldanamycin (17-DMAG) and relaxin. Tranilast
inhibits TGF-b1-mediated differentiation of bone-derived stromal
cells and proliferation of LNCaP and PC-3 prostate cancer cells
[39]. It also inhibits proliferation of several mammary carcinoma
cell lines as well as TGF-b1-induced phospho-Smad2 [40].
Tranilast was reported to be effective at improving muscle
function in BIO14.6 hamsters and mdx mouse models in vivo
[41]. SIS3, a cell-permeable pyrrolopyridine, inhibits TGF-b1
induced phosphorylation of Smad3, Smad3 binding to Smad4,
and Alk-5 induction of p3TP-lux reporter gene activity in
scleroderma fibroblasts [42]. SIS3 also has been reported to block
Smad3 phosphorylation, myostatin-induced fibrosis and prolifer-
ation of muscle fibroblasts [43]. An indirect mechanism for
inhibiting TGF-b1 signaling is through targeting Hsp90, a
molecular chaperone that plays a role in the proper folding of
proteins, the signaling of various protein kinases, and tumorigen-
esis. The Hsp90 inhibitor geldanamycin is reported to prevent
muscle atrophy [44] and recent studies indicate that geldanamycin
can inhibit TGF-b1 signaling [45,46]. The peptide hormone
relaxin has been reported to inhibit TGF-b1 signaling in renal
fibroblast cell lines in part by preventing Smad2 phosphorylation
and translocation to the nucleus [47]. Relaxin restored muscle
differentiation in C2C12 cells transfected with a TGF-b1
expression construct [48] and was shown to inhibit TGF-b1
induced collagen synthesis and deposition in myoblasts in vivo and
in vitro [49]. None of these four inhibitors, tranilast, SIS3, 17-
DMAG, or relaxin was effective in preventing TGF-b1 inhibition
of C2C12 cell muscle differentiation (Table 1D).
Two inhibitors of oxidative stress fail to restore C2C12
differentiation
Increased oxidative stress exacerbates muscle degeneration in
dystrophic muscle [50]. Two natural products that reduce
oxidative stress are resveratrol, present in red wine and peanuts
[51] and epigallocatechin-3-gallate (EGCG), the primary poly-
phenol in green tea [52]. In in vitro assays, resveratrol reduced
skeletal muscle atrophy, enhanced glucose uptake, inhibited
NFkB-mediated protein degradation, and improved muscle
function [53,54,55]. EGCG reduced oxidative stress in C2C12
cells, thereby attenuating the expression of atrogin-1 and MuRF-1,
two muscle atrophy-related ubiquitin ligases [52]. EGCG also
abrogated the expression of lipofuscin, a marker of oxidative stress,
when subcutaneously injected into mdx mice from birth, resulting
in improved muscle function, force, and physiology [56]. Neither
resveratrol nor EGCG was sufficient to overcome TGF-b1
inhibition of C2C12 cell muscle differentiation (Table 1E).
Partial recovery of C2C12 differentiation by estrogen
We tested two hormones that are known to augment
differentiation of muscle cells and interact with TGF-b1 signaling.
Androgens play a pivotal role in muscle function and development
and contribute to increased muscle mass and strength [57,58].
R1881 is a synthetic androgen that has been shown to induce
muscle differentiation in androgen receptor-transfected myoblasts
[59]. The androgen receptor works synergistically with serum
response factor, a negative regulator of Smad3-dependent
signaling, to increase muscle differentiation [59,60]. Androgen
receptor is reported to directly bind to and suppress Smad39s
essential role in TGF-b1 signaling [61]. Estrogen also interferes
with TGF-b1 signaling; estrogen receptor can bind directly to
Smad3 to inhibit its signaling function [62]. Estrogen stimulates
muscle repair and regeneration, including the activation and
proliferation of satellite cells [63], up-regulates MyoD expression,
increases muscle mass and alleviates AP-1-mediated repression of
MyoD gene expression [64,65]. Neither R1881 nor concentrations
of estrogen below 10 nM were were sufficient to overcome TGF-
b1 inhibition of C2C12 cell muscle differentiation; 10 nM
estrogen permitted partial (9%) rescue (p,0.05) (Table 1F).
Retinoic acid restores C2C12 differentiation in the
presence of TGF-b1
Retinoic acid receptors (RARs) heterodimerize with retinoid 6
receptors (RXRs) in the presence of ligands to regulate a broad array
of physiological processes. The heterodimer functions as a transcrip-
tion factor to regulate gene expression controlling differentiation, cell
survival and cell death [66]. Retinoic acid (RA) signaling has
important roles in many aspects of development including heart,
forelimb, forebrain, hindbrain, pancreas, lung and eye [67,68]. RA’s
effects on muscle differentiation are context dependent and include
activation of MyoD and myogenin in a rhabdomyosarcoma cell line,
repression of Myf5 in myoblasts and inhibition of myogenic
differentiation in embryonic limb buds and neonatal limbs
[69,70,71]. Recently, it was reported that administration of either
all-trans RA (atRA) or 9-cisRA induced C2C12 muscle differentia-
tion as assayed using a myosin heavy chain promoter driving Gaussia
luciferase, endogenous troponin T expression, endogenous MHC
expression and the formation of multi-nucleated fused myoblasts
[72]. As these reported studies were done in the absence of exogenous
TGF-b1, we examined atRA and 9-cisRA in the presence of 50 pM
TGF-b1. Both compounds permitted differentiation of the C2C12
cells in the presence of TGF-b1 comparable to the differentiation
obtained with SB431542 and TGF-b1( T a b l e1 G ) .
We used the C2C12 imaging assay to establish the dose-
responses of 9-cisRA (Figure 4) and atRA (Figure 5). In the
absence of TGF-b1, both RAs caused a reduction of about 30% in
the number of nuclei (Figures 4A and 5A). This reduction was less
than that caused by SB431542 (Figure 3A) and was quite distinct
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toxic levels of 17-DMAG ($100 nM), EGCG ($125 mM) or
resveratrol ($50 mM). As in the case of SB431542, the reduction
in nuclei by 9-cisRA or atRA coincided with increased
differentiation of the C2C12 cells (Figures 4B and 5B). The
EC50 values for differentiation in the absence of TGF-b1 were
40 nM for 9-cisRA (Figure 4B) and 26 nM for atRA (Figure 5B).
The ,60% increases in percent MHC positive nuclei observed
with 9-cisRA and atRA were comparable to the increased
differentiation detected in this assay in the presence of 500 mM
captopril or 5 nM estrogen in the absence of TGF-b1.
The dose-response of 9-cisRA and atRA on nuclei number and
percent MHC positive nucleiwasalsodetermined inthe presenceof
TGF-b1. The retinoic acids induced a dose-dependent decrease in
the number of nuclei (Figures 4C and 5C) that coincided with an
increase in differentiation (Figures 4D and 5D). The EC50 values
were 44 nM for 9-cisRA (Figure 4D) and 135 nM for atRA
(Figure 5D) for restoring differentiation in the presence of TGF-b1.
Although 9-cisRA and atRA induced ,60% increase in differen-
tiation in the absence of TGF-b1, either RA caused a ,106
increase in differentiation in the presence of TGF-b1, effectively
overcoming the TGF-b1-induced inhibition of myogenesis.
The effects of the retinoic acids on differentiation could also be
observed in the images (Figure 6). Vehicle control did not affect
C2C12 differentiation or proliferation (Figure 6A and 6E). TGF-
b1 inhibited C2C12 myotube formation and increased the
number of nuclei (Figure 6B and 6F). 9-cisRA (500 nM) or atRA
(250 nM) permitted differentiation of C2C12 cells in the presence
of TGF-b1 (Figure 6C and 6D) and reduced the TGF-b1-induced
increase in nuclei (Figure 6G and 6H).
Vitamin D prevents the retinoic acid restoration of
myogenesis in the presence of TGF-b1
There are several examples in which RA and 1a,25-dihydrox-
yvitamin D3 (vitamin D) interact to elucidate a biological response.
RA and vitamin D were shown to work synergistically to inhibit
neuroblastoma and prostate cancer cell proliferation [73,74,75]. In
contrast, antagonism between vitamin D and vitamin A, mediated
by heterodimerization of ligand bound vitamin D receptors with
RXR, also has been reported [76]. In the assay described here,
vitamin D alone had a small negative effect on C2C12 cell
differentiation in the absence of TGF-b1 and showed evidence of
toxicityat500 pMand 1 nM(datanotshown).However,vitaminD
was a potent antagonist to 500 nM 9-cisRA (IC50 of 30 pM) and
250 nM atRA (IC50 of 39 pM), as shown by the dose-response to
vitamin D in the presence of RA and TGF-b1 (Figure 7A and 7B).
Retinoic acid does not interfere with TGF-b1-induced
Smad3-dependent signaling
Biological interactions between retinoids and TGF-b signaling
vary widely and are likely to be highly cell-type and context
Figure 4. Dose-Response of 9-cisRA on C2C12 proliferation and differentiation in the absence and presence of TGF-b1. 9-cisRA
treatment inhibited cell nuclei number with an IC50 of 6 nM (A) and promoted differentiation with an IC50 of 40 nM (B) in the absence of TGF-b1.
C2C12 differentiation was inhibited by 50 pM TGF-b1 in panels C and D. 9-cisRA caused a decrease in the number of nuclei with an IC50 of 8 nM (C).
9-cisRA restored myogenesis in the presence of TGF-b1 with an IC50 of 44 nM (D).
doi:10.1371/journal.pone.0015511.g004
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signaling, either increasing or suppressing TGF-b production and/
or signaling depending on cell type, growth conditions and the
signaling response examined [77,78]. For example, atRA sup-
presses the phosphorylation of Smad2/3 and TGF-b-mediated
chondrogenesis [79,80] and inhibits TGF-b signaling in human
Figure 5. Dose-Response of atRA on C2C12 proliferation and differentiation in the absence and presence of TGF-b1. AtRA treatment
inhibited cell nuclei number with an IC50 of 7 nM (A) and promoted differentiation with an IC50 of 26 nM (B) in the absence of TGF-b1. C2C12
differentiation was inhibited by 50 pM TGF-b1 in panels C and D. AtRA caused a decrease in the number of nuclei with an IC50 of 7 nM (C). AtRA
restored myogenesis in the presence of TGF-b1 with an IC50 of 135 nM (D).
doi:10.1371/journal.pone.0015511.g005
Figure 6. C2C12 muscle differentiation is inhibited by TGF-b1 and restored by 9-cisRA or atRA. Vehicle control had no effect on C2C12
differentiation or cell proliferation (A and E) (scale bar=100 mm). TGF-b1 inhibited C2C12 myotube formation and increased cell number (B and F). 9-
cisRA (500 nM) or atRA (250 nM) restored differentiation of C2C12 cells (C and D) and reduced cell number (G and H) in the presence of TGF-b1.
doi:10.1371/journal.pone.0015511.g006
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inhibits collagen production in human lung fibroblast cells
stimulated with TGF-b1 [82]. In contrast, retinoic acid or analogs
increase expression of TGF-b1 and its receptors to facilitate TGF-
b-mediated growth inhibition in keratinocytes [83,84], promyelo-
cytic leukemia cells [85], prostate epithelial cells [86], liver stellate
cells [87] and bovine endothelial cells [88]. TGF-b and RA
pathways also cooperate to inhibit cell growth in lung epithelial
cells [89].
Various molecular mechanisms have been described for the
cross-regulation of retinoic acid and TGF-b signaling. atRA
reduces the levels of phosphorylated Smad2 and Smad3 in HL60
cells [90]. Direct protein-protein binding interactions between
RAR-gamma and Smad3 were reported [81]. In mouse
chondrocyte cell cultures, the protein thymine guanine-interacting
factor (TGIF) binds to the retinoic response element and Smad2
and Smad3 to interfere with transcriptional activation of the
respective pathways; it was proposed that activation of either
pathway releases TGIF to inhibit the other pathway [80].
TGF-b1 inhibition of muscle differentiation is mediated through
Smad3 which binds directly to the myogenic transcription factors
MyoD and MEF2 [9,10]. To begin to examine the mechanism for
RA preventing the TGF-b1 inhibition of muscle differentiation
under the conditions of the assay described here, we transfected
the TGF-b1-inducible, Smad3-dependent reporter gene SBE12-
lux into C2C12 cells (Figure 8). TGF-b1 increased the expression
of luciferase from the reporter. This increase was fully inhibited by
1 mM SB431542, but was not altered by the presence of 10 nM or
1 mM atRA or 9-cisRA. As activation of SBE12-lux requires
proper activity of the receptors for TGF-b1 and the Smad3 and
Smad4 proteins, this result suggests that atRA is acting
downstream of these components of TGF-b1 signaling to
overcome the anti-myogenic effect of TGF-b1.
Conclusions
We report a cell-based assay using high content imaging to
quantify myoblast differentiation by the presence of MHC
expression surrounding each nucleus in the field. The specific
conditions chosen here precluded detecting some agents that
accelerate C2C12 differentiation into multinucleate myotubes in
the absence of TGF-b1; however, the assay conditions were
optimized to detect agents that overcome the effect of TGF-b1o n
C2C12 differentiation. As with any in vitro screening assay, C2C12
differentiation will miss some agents that are active in vivo; the
inability of losartan to be detected in the assay provides an
example of this limitation.
Of the 13 agents tested, only atRA and 9-cisRA were effective in
fully restoring C2C12 differentiation in the presence of TGF-b1.
The identification of RAs is intriguing in that some retinoids are
already approved for human therapy, most notably for the
treatment of acute promyelocytic leukemia [91] and some skin
disorders [92]. Further studies are needed to determine if RAs
ameliorate symptoms in muscle disease that are due to poor
muscle regeneration caused by high constitutive levels of TGF-b1.
Also, it is important to note that there also are well-known adverse
effects of using retinoids in humans. The two most commonly
Figure 7. Vitamin D prevents retinoic acid mediated rescue of differentiation in TGF-b1 treated C2C12 cells. C2C12 cells were treated
with 50 pM TGF-b1 and either 500 nM 9-cisRA (A) or 250 nM atRA (B) and increasing concentrations of vitamin D for 96 hours. Increasing
concentrations of vitamin D reduced the percent of MHC positive nuclei, i.e. myoblast differentiation, with an IC50 of 30 pM in the presence of 9-
cisRA (A) or 39 pM in the presence of atRA (B).
doi:10.1371/journal.pone.0015511.g007
Figure 8. Neither 9-cisRA nor atRA inhibit TGF-b1 induced
activation of the Smad3-dependent reporter gene, SBE12-lux.
SBE12-lux activity was normalized to treatment with 50 pM TGF-b1 set
to 100%. TGF-b1-induced luciferase activity was inhibited by 1 mM
SB431542. atRA and 9-cisRA did not inhibit TGF-b1 activation of SBE-lux.
doi:10.1371/journal.pone.0015511.g008
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with generalized muscle stiffness syndrome and myalgia in some
individuals [93]. Other adverse effects of oral retinoids include
dryness of mucous membranes and eyes, increase in serum
triglycerides and teratogenicity [94]. So far, the RXR ligands,
rexinoids, appear to be less toxic, i.e., the major side-effect of
bexarotene/Targretin is hyperglyceridaemia [95,96,97]. A recent
review lists 11 retinoids, 2 rexinoids and 4 atypical retinoids in
clinical trials or approved for therapy [66]. The quantitative assay
described here will be useful for evaluating less-toxic retinoids and
also combinations of agents that may permit lower doses of
retinoids to be effective in allowing myoblast differentiation in the
presence of TGF-b1.
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